Previous Article | Next Article 
J Virol, August 1998, p. 6758-6769, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Multiple Enzymatic Activities Associated with
Recombinant NS3 Protein of Hepatitis C Virus
Paola
Gallinari,
Debra
Brennan,
Chiara
Nardi,
Mirko
Brunetti,
Licia
Tomei,
Christian
Steinkühler, and
Raffaele
De Francesco*
Istituto di Ricerche di Biologia Molecolare
P. Angeletti (IRBM), 00040 Pomezia (Rome), Italy
Received 13 February 1998/Accepted 30 April 1998
 |
ABSTRACT |
The hepatitis C virus (HCV) nonstructural 3 protein (NS3) contains
at least two domains associated with multiple enzymatic activities; a
serine protease activity resides in the N-terminal one-third of the
protein, whereas RNA helicase activity and RNA-stimulated nucleoside
triphosphatase activity are associated with the C-terminal portion. To
study the possible mutual influence of these enzymatic activities, a
full-length NS3 polypeptide of 67 kDa was expressed as a nonfusion
protein in Escherichia coli, purified to homogeneity, and
shown to retain all three enzymatic activities. The protease activity
of the full-length NS3 was strongly dependent on the activation by a
synthetic peptide spanning the central hydrophobic core of the NS4A
cofactor. Once complexed with the NS4A-derived peptide, the full-length
NS3 protein and the isolated N-terminal protease domain cleaved
synthetic peptide substrates with comparable efficiency. We show that,
as in the case of the isolated protease domain, the protease activity
of full-length NS3 undergoes inhibition by the N-terminal cleavage
products of substrate peptides corresponding to the NS4A-NS4B and
NS5A-NS5B. We have also characterized and quantified the NS3 ATPase,
RNA helicase, and RNA-binding activities under optimized reaction
conditions. Compared with the isolated N-terminal and C-terminal
domains, recombinant full-length NS3 did not show significant
differences in the three enzymatic activities analyzed in independent
in vitro assays. We have further explored the possible interdependence
of the NS3 N-terminal and C-terminal domains by analyzing the effect of
polynucleotides on the modulation of all NS3 enzymatic functions. Our
results demonstrated that the observed inhibition of the NS3
proteolytic activity by single-stranded RNA is mediated by direct
interaction with the protease domain rather than with the helicase
RNA-binding domain.
 |
INTRODUCTION |
Hepatitis C virus (HCV) is a member
of the Flaviviridae and is now recognized as the major cause
of both parenterally transmitted and community-acquired non-A, non-B
hepatitis (30). Chronic HCV infection, which develops in
more than half of afflicted individuals, has also been linked to the
development of liver cirrhosis and of hepatocellular carcinoma
(6). Although the rate of new infections has been
significantly reduced as a result of the introduction of reliable blood
tests, it has been estimated that at least 1% of the world's
population is affected by the desease (1). So far, no
efficient therapy and no vaccine is available.
HCV was identified by molecular cloning in 1989 (8). The
viral genome is a 9.5-kb, positive-sense single-stranded RNA
(ssRNA) molecule that contains a single open reading frame encoding
a polyprotein of 3,010 to 3,030 amino acids (9, 19, 35, 61). The ORF is flanked by 5' and 3' untranslated regions (15, 41, 62,
67, 68). The HCV polyprotein undergoes proteolytic processing by
both host signal peptidases and viral proteases (3, 12, 17, 18,
26-28, 42, 43, 51, 53, 65), giving rise to at least 10 mature proteins, which are encoded on the viral RNA in the
following order:
NH2-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. C,
E1, and E2 are believed to be viralstructural proteins, whereas the role of p7 has not been established. The remaining viral proteins (NS2 to NS5B) are believed to be nonstructural proteins, i.e., components of the viral replication machinery.
Whereas the structural HCV proteins arise through the action of
cellular proteinases, two viral enzymes are required for the maturation
of the nonstructural region of the polyprotein. The NS2-NS3 junction is
cleaved by a zinc-dependent autoproteinase composed of NS2 and the
N-terminal one-third of the NS3 protein (17, 27). The
C-terminal remainder of the HCV polyprotein is further processed by the
serine protease contained within the NS3 protein to give rise to mature
NS3 (67 kDa), NS4A (6 kDa), NS4B (26 kDa), NS5A (56 to 58 kDa), and
NS5B (65 kDa) proteins (3, 11, 18, 46, 65). The location of
the sites cleaved by the NS3 protease within the HCV polyprotein has
been obtained by N-terminal sequencing of the mature NS4A, NS4B, NS5A,
and NS5B proteins. Based on a comparative analysis of the sequences
flanking the cleaved peptide bonds, it has been possible to derive the following consensus sequence for the NS3-dependent cleavage site: Asp/GluXaa4Cys/Thr-Ser/Ala (18). The catalytic
domain of the NS3 protease has been mapped to the N-terminal
180-amino-acid region of NS3, which contains a characteristic serine
protease catalytic triad (2, 14, 24, 40, 56, 63). Although the N-terminal serine protease domain of NS3 shows enzymatic activity on its own, NS4A is a protease cofactor essential for efficient proteolytic processing. The degree of NS4A activation depends on the
location of the cleavage site (2, 13, 43, 64). A
14-amino-acid, hydrophobic region of NS4A has been identified as being
sufficient for the stimulation of the NS3 protease (7, 39, 44, 52,
66). In addition to the N-terminal protease domain, the
C-terminal two-thirds of the NS3 protein contains conserved sequence
motifs which are the hallmark of RNA helicases (16, 32).
Various forms of recombinant proteins containing the C-terminal domain
of NS3 have been shown to possess RNA-stimulated nucleoside
triphosphatase (NTPase) (22, 49, 59) and RNA helicase
(20, 31, 36, 49, 60) activities. The minimal requirement for
both these activities lies in the C-terminal 465 amino acids of NS3
(36). The NS3 helicase can unwind double-stranded RNA
(dsRNA) as well as dsDNA and RNA-DNA heteroduplexes in the 3'-to-5'
direction by using any nucleoside triphosphate (NTP) or dNTP as the
energy source (20, 21, 60). Mutations of the conserved
residues in the ATPase and helicase motifs severely impair both
functions (25, 37).
The three-dimensional structures of the NS3 protease domain, both alone
(45) and in complex with NS4A-derived peptides designed to
include the essential NS3-binding region (38, 69), were recently determined by X-ray crystallography. Analysis of the three-dimensional structures has revealed a chymotrypsin-like fold and a structural zinc-binding site. The crystal structure of the
C-terminal, 451-residue helicase domain of NS3 has also been determined
(70), revealing two RecA-like domains containing the
helicase motifs and a third, C-terminal domain that is unique to the
HCV enzyme.
To date, the study of the HCV protease and helicase enzymatic
activities on the two separate domains has proved to be a useful approach to dissect the multiple functions of the full-length protein.
The major and obvious limitation is that the structural and catalytic
properties of the NS3 protein may not be accurately represented by
studies on independent domains. In particular, information on the
possible mutual influence of the various enzymatic activities requires
the characterization of a more physiologically relevant protein. To
date, these kinds of studies have been hampered by the difficulties in
obtaining sufficient amounts of soluble and pure full-length NS3
enzyme. Several reports (29, 47) have recently focused on
the protease and RNA helicase activities associated with HCV
full-length NS3-NS4A complexes partially purified at relative low
yields from eukaryotic cells.
Here we describe the overexpression of a native form of full-length NS3
protein in E. coli. We report the procedure used to purify
it to homogeneity in milligrams amounts and the characterization of its
enzymatic properties. We have characterized the serine protease
activity of the full-length NS3 protein to compare it with that of the
isolated protease domain. We have also analyzed and quantified NS3
ATPase, RNA helicase, and RNA-binding activities under optimized
reaction conditions. Finally, we have explored the possible
interdependence of the two domains by analyzing the effect of
polynucleotides and protease inhibitors on the modulation of all NS3
enzymatic functions.
 |
MATERIALS AND METHODS |
Expression and purification of the NS3 protein from
bacteria.
The NS3 protease domain from HCV BK (amino acids 1027 to
1207) was expressed in Escherichia coli and purified as
previously described (56). A cDNA fragment encoding the
full-length (FL) NS3 polypeptide (amino acids 1027 to 1657 of the HCV
BK polyprotein) was obtained by PCR and cloned downstream of the T7
promoter of the pT7-7 vector, in frame with the first ATG of the
protein of gene 10 of the T7 phage. The resulting construct, pT7 NS3
FL, was sequenced with an Applied Biosystems model 373 DNA sequencer. The NS3 protein was expressed in E. coli BL21 (DE3)
(58) by a method modified from the one described in
reference 50. A 1-liter liquid culture derived from
a single transformed bacterial colony was grown at 37°C to an
absorbance at 600 nm of 0.8 in M9 modified minimal medium (5 g of
glucose per liter, 1 g of ammonium sulfate per liter, 100 mM
potassium phosphate [pH 7], 5 µM biotin, 7 µM thiamine, 0.5%
Casamino Acids, 0.5 mM MgSO4, 0.5 mM CaCl2, 13 µM FeSO4, 50 mg of ampicillin per liter). It was then
cooled to 18°C, made up 100 µM ZnCl2, and induced with
600 µM IPTG (isopropyl-
-D-thiogalactopyranoside) for
22 h at 18°C. All subsequent operations were performed at 4°C
unless otherwise indicated. Cells were harvested and then disrupted
with a Microfluidizer (model 110-S) in lysis buffer (25 mM HEPES [pH
7.6], 1 mM EDTA, 20% glycerol, 0.3 M NaCl, 0.1% n-octyl-
-D-glucopyranoside [Calbiochem], 3 mM dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride, Complete
[Boehringer] protease inhibitor mixture). The insoluble material was
pelleted at 27,000 × g for 30 min in a Sorvall SS34
rotor. The clarified supernatant, containing about 90% of the
recombinant protein, was filtered through DEAE-Sepharose Fast Flow
resin (Pharmacia) preequilibrated in lysis buffer. This sample was
concentrated by 50% ammonium sulfate precipitation and dialyzed
against lysis buffer containing 0.1 M NaCl, and NS3 was purified by
fast protein liquid chromatography (Pharmacia), as follows. The
dialyzed sample was loaded onto a 10-ml High Trap heparin-Sepharose
column (Pharmacia) and eluted with a 0.1 to 1 M NaCl linear gradient in
a buffer containing 25 mM HEPES [pH 7.6], 1 mM EDTA, 20% glycerol,
0.1% n-octyl-
-D-glucopyranoside, and 3 mM
DTT (buffer A). The protein peak was detected in fractions containing
approximately 0.35 M NaCl, which were then pooled, dialyzed against
buffer A containing 0.2 M NaCl, and loaded onto a 2-ml
poly(U)-Sepharose affinity column (Pharmacia). After a wash with 5 column volumes of the same buffer, the NS3 protein was eluted in a
>95% pure form with buffer A
1 M NaCl. Protein stocks were
quantified by amino acid analysis and stored at
80°C at 5 to 20 µM in buffer A-50% glycerol-0.5 M NaCl after being subjected to
shock-freezing in liquid nitrogen. Control experiments had shown that
this freezing procedure does not affect the NS3 protease and helicase
specific activity. NS3 was >95% pure as judged by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). N-terminal
sequencing of the purified protein was performed on an Applied
Biosystems model 470A gas phase sequencer.
Gel filtration chromatography.
The native molecular weight
of NS3 protein purified from bacteria was determined on a Pharmacia
Superdex 200 HR 10/30 column in a buffer containing 25 mM HEPES (pH
7.6), 1 mM EDTA, 10% glycerol, 0.3 M NaCl, 0.1%
n-octyl-
-D-glucopyranoside, and 3 mM DTT. The flow rate was 0.3 ml/min, and 0.6-ml fractions were collected and
analyzed by Western blotting. Blue dextran (2,000 kDa), aldolase (153 kDa), bovine serum albumin (67 kDa), and RNase A (13.7 kDa) were
obtained from Pharmacia and used as molecular mass standards.
Peptides and HPLC protease assays.
The peptide substrate
derived from the NS4A-NS4B cleavage sequence (acetylated
[Ac]-DEMEEC-ASHLPYK-NH2) was purchased from Peptides
International. All the other peptides were synthesized by solid-phase
synthesis based on Fmoc/t-Bu chemistry, as described previously
(5, 54). The identity of the peptides was determined by mass
spectrometry and amino acid analysis. The concentration of stock
peptide aliquots, prepared in buffered aqueous solutions and kept at
80°C until use, was determined by quantitative amino acid analysis
performed on HCl-hydrolyzed samples.
If not specified differently, cleavage assays were performed in 57 µl
of 50 mM Tris-HCl (pH 7.5)-2%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS;
Calbiochem)-50% glycerol-30 mM DTT to which 3 µl of NS4A-NS4B peptide substrate was added. As the protease cofactor, a peptide spanning the central hydrophobic core (residues 21 to 34) of the NS4A
protein carrying a three-lysine solubilizing tag at the N terminus was
used (5). The NS4A-derived peptide Pep4AK
(KKKGSVVIVGRIILSGR-NH2) was preincubated for 15 min at
23°C with 20 nM NS3, and the reactions were started by addition of
the substrate. Incubation times at 23°C were chosen to obtain <10%
conversion. Reactions were stopped by the addition of 40 µl of 1%
trifluoroacetic acid. Cleavage of peptide substrates was determined by
high-pressure liquid chromatography (HPLC) with a Merck-Hitachi
chromatograph equipped with an autosampler, as described previously
(5, 56). Cleavage products were quantified by integration of
chromatograms with respect to appropriate standards. Initial rates of
cleavage were determined on samples with <10% substrate conversion.
Kinetic parameters were calculated from nonlinear least-squares fit of
initial rates as a function of substrate concentration with the aid of
a Kaleidagraph software, assuming Michaelis-Menten kinetics.
The dissociation constant of the NS3-Pep4AK complex was calculated from
measurements of the rate of proteolysis (
V0) by
nonlinear
least-squares fit to the equation:
V =
V0 + (
Vmax[Pep4AK])/(
Kd + [Pep4AK]) (
5).
The 50% inhibitory concentrations (IC
50) of the peptides
Ac-DEMEEC-OH and Ac-EDVVCC-OH and of ssRNA inhibitors were
calculated
from protease assay experiments performed in the presence of
increasing
concentrations of inhibitor. In the ssRNA inhibition
experiments,
either an 18-mer oligouridylic acid
[oligo(U)
18] (Genset) or polyuridylic
acid [poly(U)]
(Pharmacia) was used, and in both cases the inhibitor
concentrations
were expressed as UMP concentrations due to the
size heterogeneity of
ssRNA molecules in the poly(U) sample. The
IC
50s were
obtained by multiparameter logistic fitting of the
experimental data.
Protease assays on in vitro-translated substrates.
In vitro
translation of the HCV proteins NS4A-NS4B (residues 1649 to 1964) and
NS5A-NS5B
C51 (residues 1965 to 2470) was described previously
(55).
In vitro transcription was performed with T7 RNA polymerase
(Stratagene). The transcripts were translated for 1 h at 30°C
in
the presence of [
35S]methionine (1,175 Ci/mmol; Dupont
NEN) with an RNA-dependent
rabbit reticulocyte lysate (Promega).
Aliquots of purified NS3
were added to the translated protein
substrates in the absence
or presence of 15 µM Pep4AK, and the
mixtures were incubated for
60 min at 30°C. Cleavage of radiolabelled
precursors was assessed
by SDS-PAGE followed by autoradiography.
NTPase activity assay.
NTPase activity was directly
determined by monitoring [
-32P]ATP hydrolysis by
thin-layer chromatography. Protein titration assays were carried out by
incubating 1.25 to 80 nM NS3 FL protein for 30 min at 37°C under
standard conditions: 25 mM morpholinepropanesulfonic acid (MOPS)-NaOH
(pH 7)-2.5 mM DTT-2.5 U of RNasin (Promega)-100 µg of bovine serum
albumin (BSA) per ml-3 mM MgCl2-1 mM ATP-2 µCi of
[
-32P]ATP (6,000 Ci/mmol, 10 mCi/ml; Dupont NEN) with
or without 0.1 mM poly(U) (see above) in a final volume of 10 µl.
Poly(U) titration experiments were performed by incubating 2 nM enzyme
in the presence of increasing concentrations of poly(U) (0.78 to 100 µM UMP). Portions (0.5 µl) of each reaction mixture were spotted
onto polyethyleneimine-cellulose sheets and developed by ascending
chromatography in 150 mM LiCl-150 mM formic acid (pH 3.0). The
cellulose sheets were dried, and released [32P]phosphoric
acid was quantified with a PhosphorImager by volumetric integration
with ImageQuant software.
Helicase and RNA-binding assays.
The partially
double-stranded RNA substrate is schematically described in Fig. 7A.
The substrate was obtained by annealing the two complementary RNA
oligonucleotides, 5'-AGAGAGAGAGGUUGAGAGAGAGAGAGUUUGAGAGAGAGAG-3' (40-mer, template strand) and
5'-CAAACUCUCUCUCUCUCAACAAAAAA-3' (26-mer, release strand),
synthesized by Genset and purified on a 20% polyacrylamide-7 M urea
denaturing gel. The release strand was 5'-end labelled with
[
-32P]ATP by using T4 polynucleotide kinase
(Pharmacia) before the annealing reaction. The two RNA oligonucleotides
were combined at a molar ratio of 3:1 (template/release), and annealing
was performed by denaturation for 5 min at 80°C followed by slow
renaturation at 23°C in 20 mM Tris-HCl (pH 8)-0.5 M NaCl-1 mM EDTA.
The partial duplex RNA was purified on a G50-80 Sephadex spun column
and stored at
20°C in H2O containing 0.25 U of RNasin
(Promega) per µl.
Unless otherwise specified, the NS3 helicase activity assay was
performed in 20 µl reaction volume containing 25 mM MOPS-NaOH
(pH 7),
2.5 mM DTT, 2.5 U of RNasin, 100 µg of BSA per ml, 3 mM
MgCl
2, 1.25 to 80 nM NS3 protein, and 1 nM
32P-labelled partial duplex RNA substrate. After
preincubation for
15 min at 23°C, 3 mM ATP was added to start the
helicase reaction.
This was carried out at 37°C for 30 min and then
stopped by adding
5 µl of termination buffer (0.1 M Tris [pH 7.5],
20 mM EDTA, 0.5%
SDS, 0.1% Nonidet P-40, 0.1% bromophenol blue,
0.1% xylene cyanol,
25% glycerol). Aliquots (8 µl) were analyzed on
a native 8% polyacrylamide
gel containing 0.5× Tris-borate-EDTA.
Strand separation was visualized
by autoradiography, and the efficiency
of the helicase reaction
was calculated by quantification of the
radioactivity with a PhosphorImager
and ImageQuant software. The
percent unwinding was calculated
as the ratio of the radioactivity
associated with the release
strand and total radioactivity associated
with both the unwound
substrate and the released strand.
Gel retardation reaction mixtures (20 µl) contained 25 mM MOPS-NaOH
(pH 7.0), 2.5 mM DTT, 2.5 U of RNasin, 100 µg of BSA per
ml, 3 mM
MgCl
2, 5 to 80 nM NS3 protein, and 1 nM
5'-
32P-labelled 26-mer ssRNA oligonucleotide corresponding
to the release
strand. After being incubated for 30 min at 37°C in
the absence
or presence of 5 mM ATP, the samples were adjusted to 5%
glycerol
and were electrophoresed in a native 6% polyacrylamide gel
containing
0.25× Tris-borate-EDTA.
 |
RESULTS |
Expression and purification of the full-length NS3 protein.
For the production of large amounts of FL NS3 protein (amino acids 1027 to 1657), we devised a method involving expression and purification
from E. coli. To this end, we chose a T7-based expression
vector and decided not to rely on a fusion protein system to obtain an
enzyme as close as possible to the native one. In preliminary
experiments, we successfully expressed this protein in E. coli by using the standard Luria-Bertani medium for bacterial
cultures and a temperature of 37°C for the IPTG induction of
expression. Nevertheless, the enzyme produced by this method was
quantitatively found in an insoluble form (data not shown). Therefore,
we tried to push the system toward the expression of a more soluble
protein and to minimize the formation of inclusion bodies, normally
associated with the presence of large amounts of misfolded protein. To
this end, transformed bacterial cultures were grown in a defined
modified minimal medium and after exponential growth at 37°C to the
desired optical density, induction with IPTG was carried out at 18°C
for 22 h. Similar methods have been demonstrated to significantly
improve the yields and to simplify the purification of several proteins
(50). In addition, to provide a source of the structural
zinc required for the proper folding of the enzyme (10, 57),
100 µM ZnCl2 was added just before induction to minimize
misfolding. About 90% of NS3 (as shown in Fig.
1A and in Western blot experiments [data
not shown]) was recovered in a soluble form upon disruption of cells
in a glycerol- and 0.1%
n-octyl-
-D-glucopyranoside-containing
hypertonic buffer. Only glycerol was strictly required for solubility,
whereas the presence of detergents was optional. After filtration
through DEAE-Sepharose to separate nucleic acids and concentration by ammonium sulfate precipitation, NS3 was further purified by two subsequent chromatographic steps on High Trap heparin-Sepharose and
poly(U)-Sepharose (Fig. 1A). The latter purification step was very
effective due to the high affinity of the enzyme for ssRNA (see below).
The purified enzyme was homogeneous, as judged by SDS-PAGE (Fig. 1A).
Experimental sequence analysis revealed the removal of the N-terminal
methionine and alanine residues, yielding the sequence P-I-T-A-Y-S-S-Q,
analogous to what has already been observed in the purified NS3
protease domain (56). This method yielded about 8 mg of
purified NS3 from 1 liter of culture at a concentration of 1.5 mg/ml.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Purification of the full-length NS3 protein from
E. coli. (A) SDS-PAGE analysis of the purification steps.
Lanes: 1, total extract; 2, soluble fraction; 3, inclusion bodies; 4, DEAE-Sepharose flowthrough; 5, 50% ammonium sulfate cut; 6, High Trap
heparin-Sepharose; 7, poly(U)-Sepharose. M.W., molecular mass markers
in kilodaltons. (B) Gel filtration analysis. A UV elution profile of a
Superdex 200 analytical column is shown. Fractions of 0.6 ml were
collected. The peaks in the chromatogram correspond to the monomeric
and aggregated NS3 protein identified by Western blotting. The
positions of the peaks corresponding to the molecular mass standard
proteins are indicated by arrows. A280, absorbance at 280 nm.
|
|
To investigate the multimerization or aggregation state of NS3, 500 µg of a purified preparation was applied to a Pharmacia
Superdex 200 gel filtration column. The elution profile was monitored
by measuring
UV absorbance at 280 nm (Fig.
1B), and the eluted
fractions were
analyzed by Western blotting with a specific anti-NS3
antiserum (data
not shown). More than 95% of NS3 eluted in close
proximity to the BSA
(67-kDa) marker, in agreement with the predicted
molecular mass of NS3
monomeric form (67 kDa). Only a small fraction
of the protein eluted in
the column void volume (

2,000 kDa).
These data indicate that the
purification conditions used yielded
a monomeric, nonaggregated
protein.
Protease activity on in vitro-translated substrates.
To assay
the trans-cleavage activity of the purified NS3 on HCV
polyprotein precursors, we incubated the enzyme at 100 nM with
35S-labelled precursor proteins NS4A-NS4B and
NS5A-NS5B
C51, synthesized by in vitro translation from the
appropriate RNAs. To assess the dependency of NS3 protease activity on
the NS4A cofactor, the experiments were performed in the presence or
absence of a large excess (15 µM) of an NS4A-derived peptide,
spanning the central hydrophobic core (residues 21 to 34) of the NS4A
protein (Pep4AK). As shown in Fig. 2, no
cleavage was detectable on either protein substrate in the absence of
the cofactor whereas processing was evident in the samples in which
Pep4AK was added. Similar results were obtained when the full-length
NS5A-NS5B precursor was used as the substrate (data not shown).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Full-length NS3 protease activity on in vitro-translated
precursor substrates. NS4A-NS4B and NS5A-NS5B C51 precursor proteins
were synthesized by in vitro translation of the corresponding RNAs in
the presence of [35S]methionine, as described in
Materials and Methods. An NS3 stock solution was diluted to 143 nM in 7 µl of 25 mM HEPES (pH 7.5)-1 mM EDTA-50% glycerol-3 mM DTT and
preincubated in the absence or presence of 15 µM Pep4AK for 10 min at
23°C. Then 3 µl of the appropriate in vitro-translated precursor
was added to the protein and the mixture was incubated for 1 h at
30°C. Reactions were terminated by the addition of 20 µl of SDS
sample buffer, and 10 µl-aliquots were analyzed by SDS-PAGE followed
by autoradiography. Lanes: 1, reactions in the absence of Pep4AK; 2, reactions in the presence of Pep4AK; 3, control samples in the absence
of NS3 protein and in the presence of Pep4AK. Bands corresponding to
the 5A/B C51 and 4AB substrates and to the 5A and 4B products are
indicated. The complementary products (5B C51 and 4A, respectively)
were not detected in the gel system used because of the small size.
M.W., molecular mass markers in kilodaltons.
|
|
This stringent requirement for NS4A in NS4A-NS4B and NS5A-NS5B
trans processing in vitro was not detected with the isolated
NS3 protease domain in analogous experiments (
55), but our
finding
is in agreement with the study of Hamatake et al.
(
23), who
compared the
trans-cleavage activity of
purified FL NS3 and NS3-NS4A
complex in the same type of assay.
Protease activity on synthetic peptide substrates.
To
determine whether the purified NS3 protein was enzymatically active on
a synthetic peptide substrate, aliquots were incubated with the 13-mer
peptide Ac-DEMEECASHLPYK-NH2, derived from the NS4A-NS4B
cleavage site (5). The cleavage efficiency was strictly dependent on the presence of a saturating concentration of an NS4A-derived synthetic peptide (Pep4AK) (Fig.
3A). The NS4A-derived core peptide had
been demonstrated to increase the cleavage efficiency of the isolated
NS3 protease domain on similar NS4A-NS4B peptide substrates (5,
55, 56). In contrast to FL NS3, the isolated protease domain was
previously shown to possess a significant level of basal activity when
analyzed under the same experimental conditions (55, 56).
The cleavage efficiency of the Pep4AK-activated enzyme was only
partially dependent on the presence of detergents (e.g., 2% CHAPS) but
was negatively affected by the omission of glycerol from the assay
mixture (Fig. 3A). In the presence of the cofactor, a
glycerol-dependent activity increase was observed, with a plateau value
between 40 and 50% glycerol (Fig. 3B). We then analyzed the time
course of the NS3-catalyzed cleavage of NS4A-NS4B peptide at a
substrate concentration of 50 µM (Km [see Table 1]) and 20 nM enzyme. No significant loss of activity was observed for up to 2 h of incubation (Fig. 3C), indicating that the enzyme was substantially stable under the assay conditions used. A
minor deviation from linearity was visible at the 2-h time point due to
product inhibition, which starts to be significant at sufficiently high
substrate conversion (see below).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Dependence of full-length NS3 protease activity on
glycerol, CHAPS, Pep4AK, and time course of the proteolysis reaction.
NS3 protein (20 nM) was incubated with 50 µM NS4A-NS4B peptide
substrate in the absence or presence of 16 µM Pep4AK in 50 mM Tris
(pH 7.5)-30 mM DTT. The reactions were stopped by addition of 1%
trifluoroacetic acid, and cleavage products were analyzed and
quantified by HPLC. (A) Standard optimized conditions included 50%
glycerol and 2% CHAPS. The effect of omitting either CHAPS or glycerol
was evaluated in the absence and presence of Pep4AK. Reactions were
carried out at 23°C for 60 min. (B) CHAPS (2%) and increasing
concentrations of glycerol in the presence of Pep4AK were analyzed at
23°C for 60 min. (C) Increasing incubation times under standard
optimized conditions and in the presence of Pep4AK were analyzed.
|
|
Kinetic analysis of NS3 protease activity.
We performed a
kinetic analysis of the cleavage reaction of NS4A-NS4B peptide
substrate under the optimized conditions, i.e., in 50 mM Tris (pH
7.5)-50% glycerol-2% CHAPS-30 mM DTT in the presence of the NS4A
cofactor (Fig. 4A), and we found that
Km was 50.9 µM and kcat
was 5.14 min
1. These values are similar to those observed
with the recombinant protease domain alone under the same reaction
conditions (5). The Pep4AK dependence of the enzymatic
activity was used to determine the dissociation constant of the
NS3-Pep4AK complex. From the titration curve in Fig. 4B, we calculated
a Kd of 2 µM, i.e., 2.5-fold lower than the
Kd calculated for the NS3 protease domain-Pep4AK complex (5). Due to the very low basal proteolytic activity associated with the full-length NS3 protein, the maximum degree of
activation induced by Pep4AK peptide was 25-fold, a value significantly higher than the 7-fold activation measured with the protease domain alone (56). Table 1 shows a
comparison between the kinetic parameters obtained with FL NS3 and with
the isolated protease domain. Similarly to the protease domain, both
the affinity of FL NS3 for the NS4A-NS4B substrate and the dissociation
constant for Pep4AK were negatively affected by lowering the glycerol
concentration (Km > 100 µM and
Kd = 8.8 µM in 15% glycerol [data not
shown]).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Steady-state kinetic analysis of NS4A-NS4B cleavage by
full-length NS3 and kinetic determination of the dissociation constant
of the NS3-Pep4AK complex. Full-length NS3 (10 nM) was incubated under
standard conditions at 23°C for 60 min. (A) Pep4AK (16 µM) and
increasing concentrations of NS4A-NS4B peptide substrate were added.
Six data points at substrate concentrations between 15 and 500 µM
were used to calculate the kinetic parameters. Initial rates of
cleavage were determined on samples with <10% substrate conversion.
Kinetic parameters (Km = 50.9 µM, and
kcat = 5.14 min 1) were calculated
from a nonlinear least-squares fit of initial rates as a function of
substrate concentration, assuming Michaelis-Menten kinetics. (B)
NS4A-NS4B peptide substrate (50 µM) was added. NS4A peptide
concentrations were varied between 0.2 and 100 µM, and 17 duplicate
data points were determined. The dissociation constant of the
NS3-Pep4AK complex (Kd = 2 µM) was calculated
from a nonlinear least-squares fit to the equation V = V0 + (Vmax[Pep4AK]) /
(Kd + [Pep4AK]).
|
|
Inhibition of NS3 protease activity.
It has recently been
reported that hexamer synthetic peptides derived from the P-side
fragments of both the NS4A-NS4B (Ac-DEMEEC-OH) and the NS5A-NS5B
(Ac-EDVVCC-OH) cleavage sites are micromolar inhibitors of the NS3
protease domain (54). On this basis, it has been suggested
that the NS3 protease is subjected to significant product inhibition.
To assess whether product inhibition also affects the full-length
enzyme, we have performed inhibitor titration experiments on NS3
protease activity in the presence of Pep4AK cofactor with the NS4A-NS4B
substrate (Fig. 5A and B). We have found
that both product-derived peptides inhibited the NS3 activity with
IC50s in the low micromolar range (6.4 µM for
Ac-DEMEEC-OH and 3.8 µM for Ac-EDVVCC-OH).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibition of NS3 protease activity by P6-P1 product
peptides and by ssRNA. (A and B) Full-length NS3 (20 nM)
trans-cleavage activity was assayed under standard
conditions on 50 µM NS4A-NS4B peptide substrate at 23°C for 60 min
after preincubation with 16 µM Pep4AK and in the presence of
increasing concentrations of inhibitor. Seven data points at product
peptide concentrations between 1.5 and 100 µM were used. (A)
Titration of Ac-DEMEEC-OH. IC50 = 6.4 µM. (B) Titration
of Ac-EDVVCC-OH. IC50 = 3.8 µM. (C and D) A standard
cleavage assay was performed with either FL NS3 or the isolated
protease domain (20 nM) in the presence of increasing concentrations of
poly(U) or oligo(U)18. These were expressed as UMP (U)
concentration because of the size heterogeneity of the RNA molecules
contained in the poly(U) sample. (C) Poly(U) titration.
IC50 = 25.4 µM UMP for FL NS3; IC50 = 73.7 µM UMP for the NS3 protease domain. (D) Oligo(U)18
titration. IC50 = 20 µM UMP for FL NS3; IC50 = 51.7 µM UMP for the protease domain.
|
|
Since RNA homopolymers are known to modulate the NTPase-helicase
activity of both the isolated helicase domain (
31,
49,
59,
60) and the full-length protein (
29,
47), we were
interested in exploring whether RNA could affect also the protease
activity of our FL NS3 enzyme under the controlled reaction conditions
established for the HPLC assay. To this end, we performed the
standard
NS3 cleavage assay in the presence of increasing concentrations
of
either poly(U) or an 18-mer oligo(U)
18. Interestingly, both
RNA molecules significantly inhibited FL NS3 protease with similar
IC
50s of 25.4 µM UMP for the poly(U) and 20 µM UMP for
oligo(U)
18 (Fig.
5C and D). Expressed in terms of RNA
molecule concentration,
the corresponding IC
50s were 85 nM
for poly(U), assuming an average
length of about 300 nucleotides, and
1.1 µM for oligo(U)
18. To
investigate whether this
RNA-mediated inhibitory effect was due
to the binding of ssRNA to the
helicase domain of NS3 protein,
we performed similar RNA titration
experiments on the isolated
NS3 protease domain (Fig.
5C and D).
Surprisingly, a strong inhibitory
effect was evident also in this case,
with IC
50s only 2.5- to
3-fold higher than those measured
with the full-length NS3 enzyme,
i.e., 74 µM UMP for poly(U) and 51.7 µM UMP for oligo(U)
18, respectively.
This result suggests
that the inhibition observed might be mediated
by a different
RNA-binding site located in NS3 protease domain.
Interestingly, when 5 mM ATP was added to the poly(U) titration
experiments (data not shown),
a threefold decrease in the inhibition
potency was observed for
full-length NS3 (IC
50 = 75 µM UMP) whereas
the
IC
50 for the protease domain remained constant at 74 µM
[UMP],
suggesting that binding of RNA to the helicase region might
participate
in the inhibitory effect on the full-length enzyme.
NS3 ATPase activity.
Full-length NS3 displayed
poly(U)-dependent ATPase activity, which was proportional to the
concentration of enzyme added (Fig. 6A).
In the linear range of the titration (up to 2 nM protein), NS3
hydrolyzed 17 fmol of ATP per fmol of enzyme in the absence of poly(U)
and 136 fmol of ATP per fmol of enzyme in the presence of 0.1 mM
poly(U) over the course of a 30-min reaction. The degree of stimulation
induced by poly(U) was approximately eightfold. Poly(U) titration
experiments (Fig. 6B) revealed that the concentration required to reach
half-maximal ATPase activity was 0.5 µM UMP. This value was 50-fold
lower than the IC50 (25.4 µM UMP) calculated for the
inhibition of the NS3 protease activity. This would suggest that at
polynucleotide concentrations which effectively stimulate the ATPase
activity of NS3, its protease activity should not be affected.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 6.
RNA-stimulated ATPase activity of full-length NS3
protein. The ATPase activity was analyzed by incubating the NS3 enzyme
for 30 min at 37°C under standard helicase conditions: 25 mM
MOPS-NaOH (pH 7)-2.5 mM DTT-2.5 U of RNasin-100 µg of BSA per
ml-3 mM MgCl2. Then 1 mM ATP hot-cold mix containing 2 µCi of [ -32P]ATP was added in a final volume of 10 µl. (A) Protein titration assays were carried out by incubating 1.25 to 40 nM of NS3 enzyme with or without 0.1 mM poly(U) (UMP). Protein
dilutions were as in Fig. 7. The initial rates were determined on
samples with <30% substrate conversion. (B) RNA titration experiments
were performed by incubating 2 nM enzyme in the presence of increasing
concentrations of poly(U) (0.78 to 50 µM UMP). The dissociation
constant of the NS3-poly(U) complex (Kd = 0.5 µM UMP) was calculated from the nonlinear least-squares fit to the
equation V = V0 + (Vmax[U] / (Kd + [U]).
|
|
NS3 helicase activity.
The full-length NS3 helicase activity
was measured with the partially dsRNA substrate shown in Fig.
7A. Titration of NS3 under optimized
reaction conditions showed that this enzyme displayed linear helicase
activity up to 40 nM protein, where it reached a plateau at about 80%
strand displacement (Fig. 7B). Similar results were obtained with the
corresponding partially dsDNA substrate (data not shown). The addition
of NS3-specific polyclonal antibodies (65) significantly
reduced the strand displacement efficiency (Fig. 7B, lane 12),
demonstrating that no contaminants in the NS3 preparation contributed
to the unwinding activity shown in our experiments. In the absence of
ATP, the RNA substrate was not affected by addition of the enzyme (lane
10). Moreover, substitution of ATP with a nonhydrolyzable ATP analog
(
,
-methylene-ATP) reduced unwinding to background levels (Fig.
7C). When the oligo(U)18 shown to affect the protease
activity of NS3 was added to the helicase reaction mixture at a 15-fold
molar excess relative to the dsRNA substrate, strand displacement was
decreased to 33%. The same amount of oligo(U)18 inhibited
the unwinding activity to background levels when ATP was replaced with
the poorly hydrolyzed analog ATP(
)S, which by itself reduced
unwinding to 66% of the control value (Fig. 7C). Addition of the
Ac-DEMEEC-OH product inhibitor to the strand-displacement reaction did
not affect NS3 helicase activity at peptide concentrations up to 120 µM (data not shown).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 7.
Helicase activity of full-length NS3 protein. (A) The
partially dsRNA substrate used in the helicase assay. (B) An NS3 stock
solution was diluted in 25 mM MOPS (pH 7)-50% glycerol-1 mg of BSA
per ml to yield a series of diluted solutions. Portions (2 µl) of
these solutions were incubated with 1 nM 32P-labelled
partial duplex RNA substrate under standard reaction conditions, as
described in Materials and Methods. Lanes: 1, sample heated in 4%
formamide to yield the release strand ssRNA marker; 2 to 8, increasing
concentrations of full-length NS3 protein; 9, assay performed in the
absence of added NS3 protein; 10, assay performed in the absence of
ATP; 11 and 12, 3 µl of protein A-Sepharose-purified antisera against
NS5B and NS3, respectively, were preincubated with 10 nM NS3 protein in
the reaction mixture for 15 min at 23°C, before ATP addition. (C)
ATP, , -methylene-ATP (AMP-PCP), or ATP( )S (each at 5 mM) was
added after preincubation of NS3 (40 nM) with 2 nM
[32P]dsRNA substrate in the absence or presence of 30 nM
oligo(U)18 ssRNA. (D) The enzyme (20 nM) was incubated with
increasing concentrations of unlabeled dsRNA substrate (0.019 to 0.599 µM) and with 1 nM of [32P]dsRNA. Up to 0.05 µM
substrate, conversion was higher than 20%. From the 0.05 to 1.6 µM
substrate data points, initial rates were calculated and plotted
against substrate concentration. Assuming Michaelis-Menten kinetics, a
kcat/Km of 3746 s 1 M 1 and a Km of at
least 1.16 µM were determined.
|
|
To evaluate the catalytic efficiency of the unwinding activity
associated with NS3, we performed a strand displacement experiment
in
which increasing concentrations of the dsRNA substrate (0.02
to 1.6 µM) were added to 20 nM enzyme (an enzyme concentration
which showed
50% of unwinding on 1 nM substrate) in the assay.
We analyzed
substrate titration values from 0.05 to 1.6 µM (Fig.
7D), at which
conversion was less than 20%. From the theoretical
curve which fitted
our experimental data, we could calculate a
catalytic efficiency value
(
kcat/
Km) of 3746 s
1 M
1 and a Michaelis constant
(
Km) of at least 1.16 µM. From the experiment
in Fig.
7D, it is also possible to deduce that the amount of product
generated is always in excess with respect to amount of the enzyme
used
in the assay. This observation implies that the enzyme is
undergoing
multiple dsRNA-unwinding cycles.
Analysis of the helicase reaction conditions.
Since the
reaction conditions used in different laboratories to assay the NS3
helicase activity are quite different (20, 29, 31, 47, 49, 59,
60), we determined the optimal buffer, pH, and divalent and
monovalent cation concentrations for the maximal helicase activity of
the NS3 enzyme purified in our laboratory (Fig.
8). First, we found that NS3 strand
displacement efficiency was affected not only by the pH of the
reaction, but also by the nature of the buffer used (Fig. 8A and B).
MOPS was the optimal buffer among those we analyzed (Fig. 8A and data
not shown), whereas HEPES (and Tris [data not shown]) reduced the activity at all pHs tested. With MOPS, the optimal pH for the reaction
was 7.0 (Fig. 8B). We found that divalent cations, either Mg2+ or Mn2+, were strictly required and that
optimal concentrations were at least 2.5 mM (Fig. 8C). On the other
hand, the presence of increasing concentrations of monovalent cations
dramatically decreased the level of helicase activity (Fig. 8D). In
fact, the maximal activity was obtained in the absence of sodium ions.
As described in Materials and Methods, the optimized values were used
in all subsequent strand displacement experiments.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 8.
Optimization of helicase reaction conditions for the
full-length NS3 protein. The activity was quantified by determining the
percentage of unwinding on 1 nM dsRNA substrate by 40 nM enzyme, as
described in Materials and Methods. (A) MOPS (pH 6.5) or HEPES (pH 6.6, 7, 7.5, and 8) (each at 25 mM) compared in reactions performed at 0 mM
NaCl, 3 mM MgCl2, 3 mM ATP. (B) Determinations of optimal
pH were performed in 25 mM MOPS (pH 6.5, 7, 7.5, and 8), as in panel A. (C) Mg2+ and Mn2+ titration was performed in 25 mM MOPS (pH 7) at 0 mM NaCl and 3 mM ATP. (D) Na+ titration
was performed in 25 mM MOPS (pH 7)-3 mM MgCl2-3 mM ATP.
|
|
NS3 RNA-binding activity.
We analyzed the RNA-binding activity
of full-length NS3 under helicase-optimized reaction conditions on the
5'-32P-labelled 26-mer ssRNA oligonucleotide corresponding
to the release strand. The gel retardation experiment (Fig.
9) demonstrated that in the absence of
ATP, NS3 is able to form a stable complex with the ssRNA probe in a
concentration-dependent manner. Titration of NS3 RNA-binding activity
paralleled titration of NS3 helicase activity (Fig. 7B), showing
linearity up to 40 nM protein, where saturation of the free probe was
observed. In the presence of 5 mM ATP, the formation of the complex was
strongly reduced at all protein concentrations tested. This result
suggests that under standard helicase reaction conditions, ATP is
required to dissociate NS3 from RNA, implying that high-affinity
binding to ssRNA is mediated by the RNA-binding domain in the helicase
portion of the protein. Similar data were obtained with
oligo(U)18 as the ssRNA probe (data not shown). NS3 protein
was also able, in the absence of ATP, to form a stable complex on the
partially dsRNA helicase substrate, which was completely dissociated by
adding a 15-fold molar excess of oligo(U)18 (data not
shown).

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 9.
Binding activity of full-length NS3 on ssRNA. Increasing
concentrations (5 to 80 nM) of NS3 protein were analyzed in binding
reactions performed in helicase reaction mixtures (20 µl) containing
1 nM 5'-32P-labelled 26-mer ssRNA oligonucleotide
corresponding to the release strand. After a 30-min incubation at
37°C in the absence (lanes 1 to 5) or presence (lanes 6 to 10) of 5 mM ATP, 6-µl aliquots were electrophoresed in a native 6%
polyacrylamide gel containing 0.25× Tris-borate-EDTA. Lane 11 contains
a control reaction mixture in the absence of NS3 protein and ATP.
|
|
 |
DISCUSSION |
We describe here a procedure for a large-scale production of the
full-length NS3 protein from the 1b HCV genotype in E. coli and the characterization of its enzymatic activities. We have previously produced the NS3 protein in insect cells by using a baculovirus expression system (data not shown). Although the enzyme purified from eukaryotic cells possessed an efficient serine protease and NTPase/helicase activity in vitro, the total amount of pure NS3
protein obtained in this experiment was not satisfactory. Therefore, we
devised a method of producing milligram amounts of the enzyme in a
soluble form in bacteria. To this end, in contrast to previously
published reports (25, 33), we successfully expressed NS3 as
a nonfusion protein to obtain an enzyme as close as possible to the
native viral enzyme. Indeed, our biochemical data demonstrated that the
polypeptide obtained from prokaryotic cells was completely
indistinguishable from that expressed in eukaryotic systems in terms of
proper folding, oligomerization, and enzymatic activity.
Although it is likely that NS3 is stably associated with its NS4A
cofactor in HCV-infected cells, we decided to produce the mature form
of NS3 without NS4A for two reasons. First, we were interested in the
possibility of investigating the effect of the NS4A cofactor on the
protease activity of FL NS3 by using the same synthetic NS4A-derived
core peptide which had been demonstrated to increase the cleavage
efficiency of the isolated protease domain (5, 55, 56). This
has allowed a direct comparison of the proteolytic properties of the
full-length and truncated enzymes. Second, we also expressed and
purified the NS3-NS4A native complex (unpublished data), and FL NS3
would provide a useful tool to study how all the enzymatic activities
of NS3 are influenced by the presence of the full-length NS4A protein.
The synthesis of soluble protein in bacteria was crucially temperature
dependent, with induction above 23°C leading quantitatively to the
formation of insoluble aggregates. Protein induction at 18°C,
together with the use of a defined modified minimal medium, significantly improved the yield of soluble protein obtained, by
minimizing the amount of misfolded protein. The purification scheme
described in this work led to several milligrams of >95% pure NS3
from 1 liter of culture, an amount suitable both for enzymological and
structural studies and for screening of potential enzyme inhibitors.
Deletion experiments have shown that the helicase and protease domains
of NS3 can work independently of each other, with the separate
polypeptide chains expressing the respective activities (2, 14,
20, 24, 31, 36, 40, 49, 56, 60, 63). This has recently permitted
the crystallization of the NS3 protease and helicase domains (38,
45, 69, 70). Despite the apparent independence of the two
enzymatic activities, there is no evidence indicating that the
corresponding two regions of the NS3 protein are cleaved during the
virus life cycle. This could simply reflect economical packaging of
essential viral replicative components, but it could also suggest that
there is functional interdependence between the two domains. The
analysis of the relationship between the two enzymatic activities in
the context of the full-length NS3 protein could provide an insight
into the physiological role of NS3 during HCV viral infection.
Therefore, we have tried to ascertain whether the two domains have any
functional overlaps or have any interdependent regulation by any
cofactor. Our study demonstrated that the enzymatic activities
associated with recombinant full-length NS3, namely, protease, ATPase,
and helicase, do not differ significantly from those associated with
the protein individual domains.
The catalytic efficiencies displayed by the full-length protein and by
the isolated protease domain in a trans-cleavage assay under
the same experimental conditions were quite comparable, due both to
similar turnover numbers (kcat) and to similar
affinities for the same NS4A-NS4B substrate (Km)
(Table 1). Activity titration of FL NS3 with Pep4AK indicated an
apparent dissociation constant in the low micromolar range, also
comparable to that measured for the N-terminal protease domain alone.
The trans-cleavage activity of the full-length NS3 protein
was increased about 25-fold in the presence of an NS4A-derived peptide,
a value significantly higher than the 7-fold activation measured with
the isolated protease domain. This difference was due to the extremely
low basal activity associated with the full-length protein compared
with its N-terminal domain. The reason for this more stringent
requirement for NS4AK in the trans processing of the
NS4A-NS4B substrate is unknown. The NS4A cofactor might be more crucial
in the stabilization of the active conformation of the full-length
protein under our in vitro conditions. Structural studies are needed to
clarify this point. On the other hand, titration of NS4AK peptide in
the strand displacement assay caused a concentration-dependent
inhibition of the helicase activity, with an IC50 of
approximately 2 µM, consistent with the apparent dissociation
constant measured in the protease activity assay (data not shown). This
data might indicate that stabilization of the enzyme in the active
protease conformation would affect its capacity to unwind dsRNA. This
result would support a model in which NS3 could assume two alternative, mutually exclusive active conformations in the presence or absence of
NS4A cofactor. Control experiments to demonstrate the specificity of
this inhibitory effect are in progress, together with the study of the
helicase activity associated with the native NS3-NS4A complex.
The isolated protease domain of NS3 is inhibited by synthetic peptides
derived from the P6-P1 sequence of NS4A-NS4B and NS5A-NS5B cleavage
sites. The N-terminal cleavage products were demonstrated to bind to
the enzyme active site with low micromolar affinities, comparable to or
higher than those of the corresponding substrates. Although the
mechanism of this product inhibition has recently been clarified
(54), the question whether this phenomenon has any
physiological relevance is still open to debate. Hexapeptide product
inhibitors based on the NS4A-NS4B and NS5A-NS5B cleavage sites were
similarly found to efficiently inhibit the serine protease activity of
full-length NS3. Interestingly, the same peptides did not affect the
helicase activity of the protein at any of the concentrations tested.
This result suggests that complete inhibition of the NS3 protease
activity has no influence on its helicase activity.
Notably, poly(U) and oligo(U)18 RNA molecules significantly
inhibited FL NS3 protease activity with similar potency. Our results are in contrast to those described in a recent study (47),
which showed a poly(U)-mediated fivefold stimulation of the protease activity of a recombinant NS3-NS4A complex on an in vitro-translated NS5A-NS5B substrate. We have tried to reproduce this RNA-mediated activation on our full-length NS3 trans-cleavage activity by
using both NS4A-NS4B and NS5A-NS5B in vitro-translated substrates and Pep4AK as a cofactor, but we did not see any effect of adding either
poly(U) or oligo(U) at concentrations up to 2 mM UMP and 180 µM UMP,
respectively (data not shown). This discrepancy might be explained by a
different mode of interaction with RNA between the NS3 complexed with
the synthetic peptide and the native NS3-NS4A complex used by
Morgenstern et al. (47). Furthermore, the RNA-mediated inhibitory effect observed in this study did not occur through the
binding of ssRNA to the helicase domain. Indeed, similar inhibitory effects were also evident on the isolated protease domain, with IC50s only 2.5- to 3-fold higher than those measured with
the full-length NS3 enzyme. Our results suggest that the inhibition observed might be mediated by a different RNA-binding site, located in
the NS3 protease domain. The mechanism of inhibition is unknown, but
experiments are in progress to define the position of this RNA
recognition site and its relationship to the active site and the
substrate-binding site within the NS3 protease domain. One attractive
hypothesis is that the RNA might interact with a positively charged
surface in the proximity of the specificity pocket, possibly at a site
which may be involved in the recognition of the acidic residues in the
P6 region of protease substrates. The physiological significance of the
observed RNA-protease domain interaction remains unknown.
Interestingly, the recent resolution of the structure of two
picornavirus 3C chymotrypsin-like proteases (hepatitis A virus and
poliovirus) (4, 48) has revealed that a well-defined surface
with a strongly charged electrostatic potential might participate in
the recognition of the 5' and 3' untranslated regions of the RNA virus
genome.
We found that the full-length NS3 ATPase-associated activity displayed
a greater sensitivity to polynucleotide stimulation than was observed
with the C-terminal helicase domain produced in E. coli
(31, 49), although it was comparable to that shown by a
NS3-NS4A complex purified from COS cells (47). This
difference in poly(U) sensitivity therefore seems to represent a
distinct feature of the full-length enzyme relative to the C-terminal
helicase domain. The poly(U) concentration required to reach
half-maximal NS3 ATPase activity was 50-fold lower than that required
for the inhibition of half-maximal protease activity. Consistent with the protease inhibition data, this result would also support the existence of an independent RNA-binding site on the NS3 protease domain.
The helicase activity of our enzyme was evaluated by using a partially
dsRNA synthetic oligosubstrate, which allowed a better quantification
of results due to the reproducibility in the RNA oligonucleotide
labelling and annealing procedure. Quantification of the strand
displacement activity data provided a catalytic efficiency value
(kcat/Km) of about 3,700 s
1 M
1, indicating a highly active enzyme
preparation. Moreover, our data show that an NS3 helicase molecule can
undergo multiple rounds of dsRNA unwinding. As expected, we observed
that oligo(U)18 RNA had an inhibitory effect on NS3
helicase activity, probably resulting from a binding competition
between the oligo(U)18 and the 3' single-stranded region of
the RNA substrate for the same binding site on NS3.
Our results, taken together, demonstrated that the ATPase-RNA helicase
activity of full-length NS3 does not substantially differ from that of
the C-terminal helicase domain analyzed by several groups (20, 22,
31, 36, 49, 59, 60) both in terms of optimal reaction conditions
(pH, temperature, and divalent-cation dependence, inhibition by
monovalent cations, etc.) and in terms of specific activity.
Furthermore, we directly compared the efficiency of unwinding of
full-length NS3 and that of a recombinant C-terminal helicase domain (a
kind gift of G. Heilek) (25) under our standard assay
conditions and found that the two enzymes possess similar strand
displacement efficiencies, indicating that the N-terminal protease
domain has little, if any, effect on the helicase activity (data not
shown).
The ability of the HCV helicase to interact preferentially with the HCV
genomic or antigenomic RNA has not been addressed in this study. We
have shown that in the absence of ATP, NS3 protein binds ssRNA tightly
with no particular sequence specificity, analogous to the results
reported for the isolated helicase domain (20, 49). From
these experiments, we could not evaluate whether the protease region
does influence the ability of the full-length enzyme to selectively
bind RNA. A recent report has indicated that the HCV helicase may bind
preferentially to the poly(U) sequence near the 3' end of the viral
genome (34, 62). It will be of interest to assess whether
full-length NS3 shows a selectively of binding to the 3' ends of the
HCV positive and negative strands, which are presumably the initiation
sites for negative- and positive-strand RNA synthesis, respectively.
Alternatively, protein-protein interaction could confer specificity of
binding to the NS3 protein upon recruitment in the replication complex.
 |
ACKNOWLEDGMENTS |
We thank A. Pessi and E. Bianchi for peptide synthesis, P. Neuner
for oligonucleotide synthesis, R. Petruzzelli for N-terminal sequence
analysis, and M. Emili for artwork. We are grateful to G. Heilek for
the gift of the recombinant NS3 helicase domain.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Ricerche di Biologia Molecolare P. Angeletti (IRBM), Via Pontina Km
30.600, 00040 Pomezia (Rome), Italy. Phone: 39 6 91093203. Fax: 39 6 91093654. E-mail: Defrancesco{at}IRBM.it.
 |
REFERENCES |
| 1.
|
Alter, H. J.
1995.
To C or not to C: these are the questions.
Blood
85:1681-1695[Free Full Text].
|
| 2.
|
Bartenschlager, R.,
L. Ahlborn Laake,
J. Mous, and H. Jacobsen.
1994.
Kinetic and structural analyses of hepatitis C virus polyprotein processing.
J. Virol.
68:5045-5055[Abstract/Free Full Text].
|
| 3.
|
Bartenschlager, R.,
L. Ahlborn-Laake,
J. Mous, and H. Jacobsen.
1993.
Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.
J. Virol.
67:3835-3844[Abstract/Free Full Text].
|
| 4.
|
Bergmann, E. M.,
S. C. Mosimann,
M. M. Chernaia,
B. A. Malcolm, and M. N. James.
1997.
The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition.
J. Virol.
71:2436-2448[Abstract/Free Full Text].
|
| 5.
|
Bianchi, E.,
A. Urbani,
G. Biasiol,
M. Brunetti,
A. Pessi,
R. De Francesco, and C. Steinkühler.
1997.
Complex formation between the hepatitis C virus serine protease and a synthetic NS4A cofactor peptide.
Biochemistry
36:7890-7897[Medline].
|
| 6.
|
Bisceglie, A. M.
1995.
Hepatitis C and hepatocellular carcinoma.
Semin. Liver Dis.
15:64-69[Medline].
|
| 7.
|
Butkiewicz, N. J.,
M. Wendel,
R. Zhang,
R. Jubin,
J. Pichardo,
E. B. Smith,
A. M. Hart,
R. Ingram,
J. Durkin,
P. W. Mui,
M. G. Murray,
L. Ramanathan, and B. Dasmahapatra.
1996.
Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.
Virology
225:328-338[Medline].
|
| 8.
|
Choo, Q.-L.,
G. Kuo,
A. J. Weiner,
L. R. Overby,
D. W. Bradley, and M. Houghton.
1989.
Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome.
Science
244:359-362[Abstract/Free Full Text].
|
| 9.
|
Choo, Q. L.,
K. H. Richman,
J. H. Han,
K. Berger,
C. Lee,
C. Dong,
C. Gallegos,
D. Coit,
R. Medina Selby,
P. J. Barr, et al.
1991.
Genetic organization and diversity of the hepatitis C virus.
Proc. Natl. Acad. Sci. USA
88:2451-2455[Abstract/Free Full Text].
|
| 10.
|
De Francesco, R.,
A. Urbani,
M. C. Nardi,
L. Tomei,
C. Steinkühler, and A. Tramontano.
1996.
A zinc binding site in viral serine proteinases.
Biochemistry
35:13282-13287[Medline].
|
| 11.
|
D'Souza, E. D.,
E. O'Sullivan,
E. M. Amphlett,
D. J. Rowlands,
D. V. Sangar, and B. E. Clarke.
1994.
Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro.
J. Gen. Virol.
75:3469-3476[Abstract/Free Full Text].
|
| 12.
|
Eckart, M. R.,
M. Selby,
F. Masiarz,
C. Lee,
K. Berger,
K. Crawford,
C. Kuo,
G. Kuo,
M. Houghton, and Q. L. Choo.
1993.
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Biochem. Biophys. Res. Commun.
192:399-406[Medline].
|
| 13.
|
Failla, C.,
L. Tomei, and R. De Francesco.
1994.
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins.
J. Virol.
68:3753-3760[Abstract/Free Full Text].
|
| 14.
|
Failla, C.,
L. Tomei, and R. De Francesco.
1995.
An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A.
J. Virol.
69:1769-1777[Abstract/Free Full Text].
|
| 15.
|
Fukushi, S.,
K. Katayama,
C. Kurihara,
N. Ishiyama,
F.-B. Hoshino,
T. Ando, and A. Oya.
1994.
Complete 5' noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA.
Biochem. Biophys. Res. Commun.
199:425-432[Medline].
|
| 16.
|
Gorbalenya, A. E., and E. V. Koonin.
1993.
Helicases: amino acid sequence comparison and structure-function relationship.
Curr. Opin. Struct. Biol.
3:419-429.
|
| 17.
|
Grakoui, A.,
D. W. McCourt,
C. Wychowski,
S. M. Feinstone, and C. M. Rice.
1993.
A second hepatitis C virus-encoded proteinase.
Proc. Natl. Acad. Sci. USA
90:10583-10587[Abstract/Free Full Text].
|
| 18.
|
Grakoui, A.,
D. W. McCourt,
C. Wychowski,
S. M. Feinstone, and C. M. Rice.
1993.
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.
J. Virol.
67:2832-2843[Abstract/Free Full Text].
|
| 19.
|
Grakoui, A.,
C. Wychowski,
C. Lin,
S. M. Feinstone, and C. M. Rice.
1993.
Expression and identification of hepatitis C virus polyprotein cleavage products.
J. Virol.
67:1385-1395[Abstract/Free Full Text].
|
| 20.
|
Gwack, Y.,
D. W. Kim,
J. H. Han, and J. Choe.
1996.
Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein.
Biochem. Biophys. Res. Commun.
225:654-659[Medline].
|
| 21.
|
Gwack, Y.,
D. W. Kim,
J. H. Han, and J. Choe.
1997.
DNA helicase activity of the hepatitis C virus nonstructural protein 3.
Eur. J. Biochem.
250:47-54[Medline].
|
| 22.
|
Gwack, Y.,
D. Wook,
J. H. Han, and J. Choe.
1995.
NTPase activity of hepatitis C virus NS3 protein expressed in insect cells.
Mol. Cells
5:171-175.
|
| 23.
|
Hamatake, R.,
H. G. Wang,
J. A. Butcher,
M. Bifano,
G. Clark,
D. Hernandez,
S. Zhang,
J. Racela,
D. Standring, and R. Colonno.
1996.
Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity.
Intervirology
39:249-258[Medline].
|
| 24.
|
Han, D. S.,
B. Hahm,
H.-M. Rho, and S. K. Jang.
1995.
Identification of the protease domain in NS3 of hepatitis C virus.
J. Gen. Virol.
76:985-993[Abstract/Free Full Text].
|
| 25.
|
Heilek, G. M., and M. G. Peterson.
1997.
A point mutation abolishes the helicase but not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein.
J. Virol.
71:6264-6266[Abstract/Free Full Text].
|
| 26.
|
Hijikata, M.,
N. Kato,
Y. Ootsuyama,
M. Nakagawa, and K. Shimotohno.
1991.
Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis.
Proc. Natl. Acad. Sci. USA
88:5547-5551[Abstract/Free Full Text].
|
| 27.
|
Hijikata, M.,
H. Mizushima,
T. Akagi,
S. Mori,
N. Kakiuchi,
N. Kato,
T. Tanaka,
K. Kimura, and K. Shimotohno.
1993.
Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus.
J. Virol.
67:4665-4675[Abstract/Free Full Text].
|
| 28.
|
Hijikata, M.,
H. Mizushima,
Y. Tanji,
Y. Komoda,
Y. Hirowatari,
T. Akagi,
N. Kato,
K. Kimura, and K. Shimotono.
1993.
Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus.
Proc. Natl. Acad. Sci. USA
90:10773-10777[Abstract/Free Full Text].
|
| 29.
|
Hong, Z.,
E. Ferrari,
J. Wright Minogue,
R. Chase,
C. Risano,
G. Seelig,
C. G. Lee, and A. D. Kwong.
1996.
Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system.
J. Virol.
70:4261-4268[Abstract/Free Full Text].
|
| 30.
|
Houghton, M.
1996.
Hepatitis C viruses, p. 1035-1058.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Raven Press, New York, N.Y.
|
| 31.
|
Jin, L., and D. L. Peterson.
1995.
Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase.
Arch. Biochem. Biophys.
323:47-53[Medline].
|
| 32.
|
Kadaré, G., and A.-L. Haenni.
1997.
Virus-encoded RNA helicases.
J. Virol.
71:2583-2590[Free Full Text].
|
| 33.
|
Kakiuchi, N.,
M. Hijikata,
Y. Komoda,
Y. Tanji,
Y. Hirowatari, and K. Shimotohno.
1995.
Bacterial expression and analysis of cleavage activity of HCV serine proteinase using recombinant and synthetic substrate.
Biochem. Biophys. Res. Commun.
210:1059-1065[Medline].
|
| 34.
|
Kanai, A.,
K. Tanabe, and M. Kohara.
1995.
Poly(U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase.
FEBS Lett.
376:221-224[Medline].
|
| 35.
|
Kato, M.,
M. Hijikata,
Y. Ootsuyama,
M. Nakagawa,
S. Ohkosci,
T. Sugimura, and K. Shimotono.
1990.
Molecular cloning of human hepatitis C virus genome from Japanese patients with non-A non-B hepatitis.
Proc. Natl. Acad. Sci. USA
87:9524-9528[Abstract/Free Full Text].
|
| 36.
|
Kim, D. W.,
Y. Gwack,
J. H. Han, and J. Choe.
1995.
C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity.
Biochem. Biophys. Res. Commun.
215:160-166[Medline].
|
| 37.
|
Kim, D. W.,
J. Kim,
Y. Gwack,
J. H. Han, and J. Choe.
1997.
Mutational analysis of the hepatitis C virus RNA helicase.
J. Virol.
71:9400-9409[Abstract/Free Full Text].
|
| 38.
|
Kim, J. L.,
K. A. Morgenstern,
C. Lin,
T. Fox,
M. D. Dwyer,
J. A. Landro,
S. P. Chambers,
W. Markland,
C. A. Lepre,
E. T. O'Malley,
S. L. Harbeson,
C. M. Rice,
M. A. Murcko,
P. R. Caron, and J. A. Thomson.
1996.
Crystal structure of the hepatitis virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.
Cell
87:343-355[Medline].
|
| 39.
|
Koch, J. O.,
V. Lohmann,
U. Herian, and R. Bartenschlager.
1996.
In vitro studies on the activation of the hepatitis C virus NS3 proteinase by the NS4A cofactor.
Virology
221:54-66[Medline].
|
| 40.
|
Kolykhalov, A. A.,
E. V. Agapov, and C. M. Rice.
1994.
Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing.
J. Virol.
68:7525-7533[Abstract/Free Full Text].
|
| 41.
|
Kolykhalov, A. A.,
S. M. Feinstone, and C. M. Rice.
1996.
Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA.
J. Virol.
70:3363-3371[Abstract/Free Full Text].
|
| 42.
|
Komoda, Y.,
M. Hijikata,
Y. Tanji,
Y. Hirowatari,
H. Mizushima,
K. Kimura, and K. Shimotohno.
1994.
Processing of hepatitis C viral polyprotein in Escherichia coli.
Gene
145:221-226[Medline].
|
| 43.
|
Lin, C.,
B. M. Pragai,
A. Grakoui,
J. Xu, and C. M. Rice.
1994.
Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics.
J. Virol.
68:8147-8157[Abstract/Free Full Text].
|
| 44.
|
Lin, C.,
J. A. Thomson, and C. M. Rice.
1995.
A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro.
J. Virol.
69:4373-4380[Abstract/Free Full Text].
|
| 45.
|
Love, R. A.,
H. E. Parge,
J. A. Wickersham,
Z. Hostomsky,
N. Habuka,
E. W. Moomaw,
T. Adachi, and Z. Homstomska.
1996.
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.
Cell
87:331-342[Medline].
|
| 46.
|
Manabe, S.,
I. Fuke,
O. Tanishita,
C. Kaji,
Y. Gomi,
S. Yoshida,
C. Mori,
A. Takamizawa,
I. Yosida, and H. Okayama.
1994.
Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3.
Virology
198:636-644[Medline].
|
| 47.
|
Morgenstern, K. A.,
J. A. Landro,
K. Hsiao,
C. Lin,
Y. Gu,
M. S.-S. Su, and J. A. Thompson.
1997.
Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells.
J. Virol.
71:3767-3775[Abstract/Free Full Text].
|
| 48.
|
Mosimann, S. C.,
M. M. Cherney,
S. Sia,
S. Plotch, and M. N. James.
1997.
Refined X-ray crystallographic structure of the poliovirus 3C gene product.
J. Mol. Biol.
273:1032-1047[Medline].
|
| 49.
|
Preugschat, F.,
D. R. Averett,
B. E. Clarke, and D. J. T. Porter.
1996.
A steady-state and pre-steady state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain.
J. Biol. Chem.
271:24449-24457[Abstract/Free Full Text].
|
| 50.
|
Pryor, K. D., and B. Leiting.
1998.
High-level expression of soluble protein in Escherichia coli using a His6-tag and maltose-binding-protein double-affinity fusion system.
Protein Expression Purif.
10:309-319.
|
| 51.
|
Santolini, E.,
G. Migliaccio, and N. La Monica.
1994.
Biosynthesis and biochemical properties of the hepatitis C virus core protein.
J. Virol.
68:3631-3641[Abstract/Free Full Text].
|
| 52.
|
Shimizu, Y.,
K. Yamaji,
Y. Masuho,
T. Yokota,
H. Inoue,
K. Sudo,
S. Satoh, and K. Shimotohno.
1996.
Identification of the sequence of NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease.
J. Virol.
70:127-132[Abstract/Free Full Text].
|
| 53.
|
Shimotohno, K.,
Y. Tanji,
Y. Hirowatari,
Y. Komoda,
N. Kato, and M. Hijikata.
1995.
Processing of the hepatitis C virus precursor protein.
J. Hepatol.
22:87-92[Medline].
|
| 54.
| Steinkühler, C., G. Biasiol, M. Brunetti, A. Urbani, R. Cortese, A. Pessi, and R. De Francesco. Product
inhibition of the hepatitis C virus NS3 protease. Biochemistry, in
press.
|
| 55.
|
Steinkühler, C.,
L. Tomei, and R. De Francesco.
1996.
In vitro activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells.
J. Biol. Chem.
271:6367-6373[Abstract/Free Full Text].
|
| 56.
|
Steinkühler, C.,
A. Urbani,
L. Tomei,
G. Biasiol,
M. Sardana,
E. Bianchi,
A. Pessi, and R. De Francesco.
1996.
Activity of purified hepatitis C virus protease NS3 on peptide substrates.
J. Virol.
70:6694-6700[Abstract/Free Full Text].
|
| 57.
|
Stempniak, M.,
Z. Homstomska,
B. R. Nodes, and Z. Hostomsky.
1997.
The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme.
J. Virol.
71:2881-2886[Abstract/Free Full Text].
|
| 58.
|
Studier, F. W.,
A. H. Rosenberg,
J. J. Dunn, and J. W. Dubendorff.
1998.
Use of the T7 RNA polymerase to direct expression of cloned genes.
Methods Enzymol.
185:60-89.
|
| 59.
|
Suzich, J. A.,
J. K. Tamura,
F. Palmer Hill,
P. Warrener,
A. Grakoui,
C. M. Rice,
S. M. Feinstone, and M. S. Collett.
1993.
Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.
J. Virol.
67:6152-6158[Abstract/Free Full Text].
|
| 60.
|
Tai, C.-L.,
W.-K. Chi,
D.-S. Chen, and L.-H. Hwang.
1996.
The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3).
J. Virol.
70:8477-8484[Abstract/Free Full Text].
|
| 61.
|
Takamizawa, A.,
C. Mori,
I. Fuke,
S. Manabe,
S. Murakami,
J. Fujita,
E. Onishi,
T. Andoh,
I. Yoshida, and H. Okayama.
1991.
Structure and organization of the hepatitis C virus genome isolated from human carriers.
J. Virol.
65:1105-1113[Abstract/Free Full Text].
|
| 62.
|
Tanaka, T.,
N. Kato,
M. J. Cho, and K. Shimotohno.
1995.
A novel sequence found at the 3' terminus of the hepatitis C virus genome.
Biochem. Biophys. Res. Commun.
215:744-749[Medline].
|
| 63.
|
Tanji, Y.,
M. Hijikata,
Y. Hirowatari, and K. Shimotohno.
1994.
Hepatitis C virus polyprotein processing: kinetics and mutagenic analysis of serine proteinase-dependent cleavage.
J. Virol.
68:8418-8422[Abstract/Free Full Text].
|
| 64.
|
Tanji, Y.,
M. Hijikata,
S. Satoh,
T. Kaneko, and K. Shimotohno.
1995.
Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing.
J. Virol.
69:1575-1581[Abstract/Free Full Text].
|
| 65.
|
Tomei, L.,
C. Failla,
E. Santolini,
R. De Francesco, and N. La Monica.
1993.
NS3 is a serine protease required for processing of hepatitis C virus polyprotein.
J. Virol.
67:4017-4026[Abstract/Free Full Text].
|
| 66.
|
Tomei, L.,
C. Failla,
R. L. Vitale,
E. Bianchi, and R. De Francesco.
1996.
A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease.
J. Gen. Virol.
77:1065-1070[Abstract/Free Full Text].
|
| 67.
|
Tsukiyama-Koharak, D.,
N. Iizukam,
M. Kohara, and A. Nomoto.
1992.
Internal ribosome entry site within hepatitis C virus RNA.
J. Virol.
66:1476-1483[Abstract/Free Full Text].
|
| 68.
|
Wang, C.,
P. Sarnow, and A. Siddiqui.
1993.
Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome binding mechanism.
J. Virol.
67:3338-3344[Abstract/Free Full Text].
|
| 69.
|
Yan, Y.,
S. Munshi,
V. Sardana,
J. Blue,
B. Johns,
J. Cole,
C. Steinkuheler,
L. Tomei,
R. De Francesco,
L. Kuo, and Z. Chen.
1988.
Complex of NS3 proteinase and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form.
Protein Sci.
7:837-847[Medline].
|
| 70.
|
Yao, N.,
T. Hesson,
M. Cable,
Z. Hong,
A. D. Kwong,
H. V. Le, and P. C. Weber.
1997.
Structure of the hepatitis C virus RNA helicase domain.
Nat. Struct. Biol.
4:463-467[Medline].
|
J Virol, August 1998, p. 6758-6769, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pan, K.-L., Lee, J.-C., Sung, H.-W., Chang, T.-Y., Hsu, J. T.-A.
(2009). Development of NS3/4A Protease-Based Reporter Assay Suitable for Efficiently Assessing Hepatitis C Virus Infection. Antimicrob. Agents Chemother.
53: 4825-4834
[Abstract]
[Full Text]
-
Hara, H., Aizaki, H., Matsuda, M., Shinkai-Ouchi, F., Inoue, Y., Murakami, K., Shoji, I., Kawakami, H., Matsuura, Y., Lai, M. M. C., Miyamura, T., Wakita, T., Suzuki, T.
(2009). Involvement of Creatine Kinase B in Hepatitis C Virus Genome Replication through Interaction with the Viral NS4A Protein. J. Virol.
83: 5137-5147
[Abstract]
[Full Text]
-
Lundin, M., Lindstrom, H., Gronwall, C., Persson, M. A. A.
(2006). Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein.. J. Gen. Virol.
87: 3263-3272
[Abstract]
[Full Text]
-
Mackintosh, S. G., Lu, J. Z., Jordan, J. B., Harrison, M. K., Sikora, B., Sharma, S. D., Cameron, C. E., Raney, K. D., Sakon, J.
(2006). Structural and Biological Identification of Residues on the Surface of NS3 Helicase Required for Optimal Replication of the Hepatitis C Virus. J. Biol. Chem.
281: 3528-3535
[Abstract]
[Full Text]
-
Welbourn, S., Green, R., Gamache, I., Dandache, S., Lohmann, V., Bartenschlager, R., Meerovitch, K., Pause, A.
(2005). Hepatitis C Virus NS2/3 Processing Is Required for NS3 Stability and Viral RNA Replication. J. Biol. Chem.
280: 29604-29611
[Abstract]
[Full Text]
-
Zhang, C., Cai, Z., Kim, Y.-C., Kumar, R., Yuan, F., Shi, P.-Y., Kao, C., Luo, G.
(2005). Stimulation of Hepatitis C Virus (HCV) Nonstructural Protein 3 (NS3) Helicase Activity by the NS3 Protease Domain and by HCV RNA-Dependent RNA Polymerase. J. Virol.
79: 8687-8697
[Abstract]
[Full Text]
-
Prabhu, R., Khalap, N., Burioni, R., Clementi, M., Garry, R. F., Dash, S.
(2004). Inhibition of Hepatitis C Virus Nonstructural Protein, Helicase Activity, and Viral Replication by a Recombinant Human Antibody Clone. Am. J. Pathol.
165: 1163-1173
[Abstract]
[Full Text]
-
Lam, A. M. I., Rypma, R. S., Frick, D. N.
(2004). Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding. Nucleic Acids Res
32: 4060-4070
[Abstract]
[Full Text]
-
Levin, M. K., Wang, Y.-H., Patel, S. S.
(2004). The Functional Interaction of the Hepatitis C Virus Helicase Molecules Is Responsible for Unwinding Processivity. J. Biol. Chem.
279: 26005-26012
[Abstract]
[Full Text]
-
Kyono, K., Miyashiro, M., Taguchi, I.
(2004). Expression and Purification of a Hepatitis C Virus NS3/4A Complex, and Characterization of Its Helicase Activity with the Scintillation Proximity Assay System. J Biochem
135: 245-252
[Abstract]
[Full Text]
-
Frick, D. N., Rypma, R. S., Lam, A. M. I., Gu, B.
(2004). The Nonstructural Protein 3 Protease/Helicase Requires an Intact Protease Domain to Unwind Duplex RNA Efficiently. J. Biol. Chem.
279: 1269-1280
[Abstract]
[Full Text]
-
Kar, A. K., Roy, P.
(2003). Defining the Structure-Function Relationships of Bluetongue Virus Helicase Protein VP6. J. Virol.
77: 11347-11356
[Abstract]
[Full Text]
-
Goregaoker, S. P., Culver, J. N.
(2003). Oligomerization and Activity of the Helicase Domain of the Tobacco Mosaic Virus 126- and 183-Kilodalton Replicase Proteins. J. Virol.
77: 3549-3556
[Abstract]
[Full Text]
-
Hardy, R. W., Marcotrigiano, J., Blight, K. J., Majors, J. E., Rice, C. M.
(2003). Hepatitis C Virus RNA Synthesis in a Cell-Free System Isolated from Replicon-Containing Hepatoma Cells. J. Virol.
77: 2029-2037
[Abstract]
[Full Text]
-
Dziembowski, A., Piwowarski, J., Hoser, R., Minczuk, M., Dmochowska, A., Siep, M., van der Spek, H., Grivell, L., Stepien, P. P.
(2003). The Yeast Mitochondrial Degradosome. ITS COMPOSITION, INTERPLAY BETWEEN RNA HELICASE AND RNase ACTIVITIES AND THE ROLE IN MITOCHONDRIAL RNA METABOLISM. J. Biol. Chem.
278: 1603-1611
[Abstract]
[Full Text]
-
Minczuk, M., Piwowarski, J., Papworth, M. A., Awiszus, K., Schalinski, S., Dziembowski, A., Dmochowska, A., Bartnik, E., Tokatlidis, K., Stepien, P. P., Borowski, P.
(2002). Localisation of the human hSuv3p helicase in the mitochondrial matrix and its preferential unwinding of dsDNA. Nucleic Acids Res
30: 5074-5086
[Abstract]
[Full Text]
-
Levin, M. K., Patel, S. S.
(2002). Helicase from Hepatitis C Virus, Energetics of DNA Binding. J. Biol. Chem.
277: 29377-29385
[Abstract]
[Full Text]
-
Borowski, P., Lang, M., Haag, A., Schmitz, H., Choe, J., Chen, H.-M., Hosmane, R. S.
(2002). Characterization of Imidazo[4,5-d]Pyridazine Nucleosides as Modulators of Unwinding Reaction Mediated by West Nile Virus Nucleoside Triphosphatase/Helicase: Evidence for Activity on the Level of Substrate and/or Enzyme. Antimicrob. Agents Chemother.
46: 1231-1239
[Abstract]
[Full Text]
-
Rho, J., Choi, S., Seong, Y. R., Choi, J., Im, D.-S.
(2001). The Arginine-1493 Residue in QRRGRTGR1493G Motif IV of the Hepatitis C Virus NS3 Helicase Domain Is Essential for NS3 Protein Methylation by the Protein Arginine Methyltransferase 1. J. Virol.
75: 8031-8044
[Abstract]
[Full Text]
-
Tai, C.-L., Pan, W.-C., Liaw, S.-H., Yang, U.-C., Hwang, L.-H., Chen, D.-S.
(2001). Structure-Based Mutational Analysis of the Hepatitis C Virus NS3 Helicase. J. Virol.
75: 8289-8297
[Abstract]
[Full Text]
-
Borowski, P., Niebuhr, A., Mueller, O., Bretner, M., Felczak, K., Kulikowski, T., Schmitz, H.
(2001). Purification and Characterization of West Nile Virus Nucleoside Triphosphatase (NTPase)/Helicase: Evidence for Dissociation of the NTPase and Helicase Activities of the Enzyme. J. Virol.
75: 3220-3229
[Abstract]
[Full Text]
-
Tijms, M. A., van Dinten, L. C., Gorbalenya, A. E., Snijder, E. J.
(2001). A zinc finger-containing papain-like protease couples subgenomic mRNA synthesis to genome translation in a positive-stranded RNA virus. Proc. Natl. Acad. Sci. USA
10.1073/pnas.041390398v1
[Abstract]
[Full Text]
-
Tackett, A. J., Wei, L., Cameron, C. E., Raney, K. D.
(2001). Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex. Nucleic Acids Res
29: 565-572
[Abstract]
[Full Text]
-
Marin, M. S., Casais, R., Alonso, J. M. M., Parra, F.
(2000). ATP Binding and ATPase Activities Associated with Recombinant Rabbit Hemorrhagic Disease Virus 2C-Like Polypeptide. J. Virol.
74: 10846-10851
[Abstract]
[Full Text]
-
Chang, S. C., Cheng, J.-C., Kou, Y.-H., Kao, C.-H., Chiu, C.-H., Wu, H.-Y., Chang, M.-F.
(2000). Roles of the AX4GKS and Arginine-Rich Motifs of Hepatitis C Virus RNA Helicase in ATP- and Viral RNA-Binding Activity. J. Virol.
74: 9732-9737
[Abstract]
[Full Text]
-
Sbardellati, A., Scarselli, E., Amati, V., Falcinelli, S., Kekulé, A. S., Traboni, C.
(2000). Processing of GB virus B non-structural proteins in cultured cells requires both NS3 protease and NS4A cofactor. J. Gen. Virol.
81: 2183-2188
[Abstract]
[Full Text]
-
Bartenschlager, R., Lohmann, V.
(2000). Replication of hepatitis C virus. J. Gen. Virol.
81: 1631-1648
[Full Text]
-
Paolini, C., Lahm, A., De Francesco, R., Gallinari, P.
(2000). Mutational analysis of hepatitis C virus NS3-associated helicase. J. Gen. Virol.
81: 1649-1658
[Abstract]
[Full Text]
-
Butkiewicz, N., Yao, N., Zhong, W., Wright-Minogue, J., Ingravallo, P., Zhang, R., Durkin, J., Standring, D. N., Baroudy, B. M., Sangar, D. V., Lemon, S. M., Lau, J. Y. N., Hong, Z.
(2000). Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3. J. Virol.
74: 4291-4301
[Abstract]
[Full Text]
-
Paolini, C., De Francesco, R., Gallinari, P.
(2000). Enzymatic properties of hepatitis C virus NS3-associated helicase. J. Gen. Virol.
81: 1335-1345
[Abstract]
[Full Text]
-
Leyssen, P., De Clercq, E., Neyts, J.
(2000). Perspectives for the Treatment of Infections with Flaviviridae. Clin. Microbiol. Rev.
13: 67-82
[Abstract]
[Full Text]
-
Darke, P. L., Jacobs, A. R., Waxman, L., Kuo, L. C.
(1999). Inhibition of Hepatitis C Virus NS2/3 Processing by NS4A Peptides. IMPLICATIONS FOR CONTROL OF VIRAL PROCESSING. J. Biol. Chem.
274: 34511-34514
[Abstract]
[Full Text]
-
Sullivan, D. G., Wilson, J. J., Carithers, R. L. Jr., Perkins, J. D., Gretch, D. R.
(1998). Multigene Tracking of Hepatitis C Virus Quasispecies after Liver Transplantation: Correlation of Genetic Diversification in the Envelope Region with Asymptomatic or Mild Disease Patterns. J. Virol.
72: 10036-10043
[Abstract]
[Full Text]
-
Vasiljeva, L., Merits, A., Auvinen, P., Kaariainen, L.
(2000). Identification of a Novel Function of the Alphavirus Capping Apparatus. RNA 5'-TRIPHOSPHATASE ACTIVITY OF Nsp2. J. Biol. Chem.
275: 17281-17287
[Abstract]
[Full Text]
-
Tijms, M. A., van Dinten, L. C., Gorbalenya, A. E., Snijder, E. J.
(2001). A zinc finger-containing papain-like protease couples subgenomic mRNA synthesis to genome translation in a positive-stranded RNA virus. Proc. Natl. Acad. Sci. USA
98: 1889-1894
[Abstract]
[Full Text]